Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.
2023 年第四季度的收入增長了 28%。在Mounjaro和Zepbound的帶動下，新產品（i）收入在2023年第四季度增長了21.9億美元，達到24.9億美元。增長產品（ii）收入在2023年第四季度增長了9％，達到52.7億美元，由Verzenio和Jardiance領先。
Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).
管道進展包括美國食品藥品管理局批准Zepbound用於肥胖或超重併發體重相關合並症的成年人，以及根據加速批准計劃批准Jaypirca用於慢性淋巴細胞白血病或小淋巴細胞淋巴瘤。其他進展包括SYNERGY-NASH的積極結果，這是一項針對非酒精性脂肪肝炎（NASH）（也稱爲代謝功能障礙相關性脂肪性肝炎（MASH）成人的替塞帕肽的2期研究。
Business development activity included the completed acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS.
業務發展活動包括完成對POINT Biopharma Global Inc.和Mablink Biosciences SAS的收購。
Q4 2023 EPS increased 13% to $2.42 on a reported basis and increased 19% to $2.49 on a non-GAAP basis, both inclusive of $0.62 of acquired IPR&D charges.
根據報告，2023年第四季度每股收益增長了13％，至2.42美元，按非公認會計准則計算，增長了19％，至2.49美元，均包括收購的0.62美元的知識產權和開發費用。
2024 guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70.
發佈的2024年指引顯示，收入在404億美元至416億美元之間，每股收益在11.80美元至12.30美元之間，非公認會計准則每股收益在12.20美元至12.70美元之間。
